<div id="readability-page-1"><p><strong>Hims &amp; Hers Health, Inc. <span>( HIMS )</span></strong> is trading lower on Wednesday as the stock continues to digest financing-related dilution risk and positioning around its international expansion plans.</p>    <ul> <li>Hims &amp; Hers Health <span>( HIMS )</span> stock is trading at depressed levels. What’s next for HIMS stock?</li> </ul>    <h2>What’s Driving Hims &amp; Hers Health Stock?</h2>    <p>Hims &amp; Hers priced a private placement of convertible senior notes due 2032 this week, upsizing the offering to $350 million from an originally planned $300 million on strong institutional demand. The notes carry a 0.00% coupon and an initial conversion price of about $29.53 per share, a 32.5% premium to Monday's close, with an option for initial purchasers to buy up to an additional $52.5 million within 13 days.</p>    <p>Net proceeds are slated to support operational flexibility and international growth, including the proposed <strong>Eucalyptus</strong> acquisition expected to close in mid-2026. To help offset dilution concerns, the company also entered capped call transactions with an initial cap price of $50.15 per share.</p>    <h2>Critical Levels To Watch for HIMS Stock</h2>    <p>From a longer-term view, the chart is still in recovery mode after heavy damage: the stock is down 64.04% over the past 12 months and remains far below the $35.43 200-day SMA (about 37.7% under it). It's also trading below the $26.63 20-day SMA, $24.30 50-day SMA, and $24.63 100-day SMA, which keeps rallies vulnerable to sellers near those moving-average &#34;supply&#34; zones.</p>    <p>Momentum is leaning bearish right now: MACD is below its signal line and the histogram is negative, which typically means upside pressure is fading versus the prior upswing unless buyers can reclaim that baseline. Structurally, there's a short-term positive (the 20-day SMA is above the 50-day SMA), but the bigger-picture &#34;death cross&#34; from December 2025 (50-day below the 200-day) keeps the primary trend biased lower until price can retake longer-term levels.</p>    <ul> <li><strong>Key Support</strong>: $18.50 — a nearby level where buyers previously stepped in (a key pivot zone if the current pullback extends)</li> </ul>    <h2>What Is Hims &amp; Hers Health?</h2>    <p>Hims &amp; Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics and supplements.</p>    <h2>HIMS Stock Price Activity Wednesday Morning</h2>    <p><strong>HIMS Stock Price Activity:</strong> Hims &amp; Hers Health <span>( HIMS )</span> shares were down 1.11% at $22.19 at the time of publication on Wednesday, according to Benzinga Pro data.</p>    <p> <strong> Read Also:  Stock Market Today: S&amp;P 500, Nasdaq 100 Futures Gain As Street Awaits Nvidia's Q1 Report—CAVA Group, AMC Entertainment, Roblox In Focus </strong> </p>   <p><em>Image: Shutterstock</em></p></div>

HIMS

HIMY

HIMZ

<p>Hims & Hers Health (NYSE:HIMS) stock fell 1.11% to $22.19 amid concerns over financing-related dilution risks and international expansion plans. The company recently upsized a private placement of convertible senior notes to $350 million, with proceeds aimed at supporting operational flexibility and growth. Despite a short-term positive trend, the stock remains down 64.04% over the past year, trading below key moving averages, indicating bearish momentum.</p>

Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital